Caribou Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 158
- Market Cap
- -
- Website
- http://www.cariboubio.com
- Introduction
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
- Conditions
- Systemic Lupus ErythematosusLupusLupus ErythematosusLupus Nephritis
- Interventions
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Caribou Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06752876
- Locations
- 🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Caribou Biosciences, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06128044
- Locations
- 🇺🇸
The University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Caribou Biosciences, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05722418
- Locations
- 🇺🇸
Hackensack Meridian John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸CU Anschutz Medical Campus, Anshutz Cancer Pavillion, Aurora, Colorado, United States
Long-Term Follow-up Study
- Conditions
- LymphomaLymphoma, Non-HodgkinB Cell LymphomaRelapsed/Refractory Acute Myeloid LeukemiaRefractory B-Cell Non-Hodgkin LymphomaNon-Hodgkin LymphomaB-Cell Non-Hodgkin's LymphomaRelapsed Non-Hodgkin LymphomaHematologic MalignancyRelapsed/Refractory Multiple Myeloma
- Interventions
- Biological: Allogeneic CAR-T therapyBiological: Caribou-sponsored investigational therapy
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Caribou Biosciences, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05332054
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Colorado, Denver, Colorado, United States
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
- Conditions
- Non Hodgkin LymphomaLymphoma, Non-HodgkinRelapsed Non Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaB Cell LymphomaB Cell Non-Hodgkin's LymphomaLymphoma
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Caribou Biosciences, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04637763
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States